Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8849271 | 0.84 | GSK3A (0.36) | GSK3AGSK3BMGLL | |
| SCHEMBL1815774 | 0.82 | GAA (0.36) | GSK3AGSK3BMGLL | |
| SCHEMBL10579748 | 0.81 | — | — | |
| SCHEMBL2870659 | 0.79 | — | — | |
| SCHEMBL8849196 | 0.78 | ESR1 (0.36) | MAPK1 | |
| SCHEMBL2688393 | 0.78 | MAPK1 (0.45) | GSK3AGSK3BMGLLMAPK1 | |
| SCHEMBL2022741 | 0.77 | — | — | |
| SCHEMBL8849250 | 0.72 | MGLL (0.45) | GSK3AGSK3BMGLL | |
| SCHEMBL9350711 | 0.72 | ALDH1A1 (0.32) | — | |
| Bicarbonate SCHEMBL15320130 | 0.72 | MAPK1 (0.32) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714957-A1 | (METH)ACRYLATE COMPOUND PRODUCTION METHOD | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2026-03-25 | — | — | EP | claimed |
| US-20250041285-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2025-02-06 | — | — | US | claimed |
| US-20240415826-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2024-12-19 | — | — | US | claimed |
| US-20240327324-A1 | METHOD FOR PRODUCING FATTY ALDEHYDES AND DERIVATIVES THEREOF | FMC Agricultural Solutions A/S (DK) | 2024-10-03 | — | — | US | claimed |
| EP-4380916-A1 | METHOD FOR PRODUCING FATTY ALDEHYDES AND DERIVATIVES THEREOF | FMC Agricultural Solutions A/S (DK) | 2024-06-12 | — | — | EP | claimed |
| CN-117897373-A | Process for producing fatty aldehyde and derivative thereof | FMC农业解决方案股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| WO-2023229323-A1 | METHOD FOR PREPARING 6-METHOXYPYRIDIN-3-YL DERIVATIVE | 일동제약(주) | 2023-11-30 | — | — | WO | claimed |
| WO-2023012151-A1 | METHOD FOR PRODUCING FATTY ALDEHYDES AND DERIVATIVES THEREOF | BIOPHERO APS (DK) | 2023-02-09 | — | — | WO | claimed |
| WO-2022264971-A1 | METHOD FOR EVALUATING QUALITY OF SPERM | 国立大学法人東海国立大学機構 | 2022-12-22 | — | — | WO | claimed |
| WO-2022251679-A1 | NITROXIDE RADICALS FOR USE AS ANTIVIRAL TREATMENT FOR CORONAVIRUS INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-01 | — | — | WO | claimed |
| WO-2013038316-A1 | METHOD FOR PREPARATION OF BETULINIC ACID | STORA ENSO OYJ (FI) | 2013-03-21 | — | — | WO | claimed |
| WO-2012096824-A1 | PHENYLGLYOXYLIC ACID DERIVATIVES AND THEIR PREPARATION AND USE | TRANSTECH PHARMA, INC. (US) | 2012-07-19 | — | — | WO | claimed |
| WO-2012085016-A1 | PROCESS FOR CURING SURFACE-COATING COMPOSITIONS | CYTEC AUSTRIA GMBH (AT) | 2012-06-28 | — | — | WO | claimed |
| US-20100240700-A1 | PROPHYLACTIC PRETREATMENT WITH ANTIOXIDANTS | MITOS PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | claimed |
| US-20100041716-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING HYPERCHOLESTEROLEMIA | MITOS PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | claimed |
| WO-2008104683-A1 | ELECTRODE CONTAINING AT LEAST ONE NITROXIDE AND CARBON NANOTUBES | ARKEMA FRANCE (FR) | 2008-09-04 | — | — | WO | claimed |
| EP-0983334-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | Call, Krimhild (DE) | 2000-03-08 | — | — | EP | claimed |
| WO-1998055684-A1 | MULTI-COMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, MATERIALS CONTAINING LIGNIN OR SIMILAR SUBSTANCES AND METHODS FOR PRODUCING THE SAME | Consortium für elektrochemische Industrie GmbH (DE) | 1998-12-10 | — | — | WO | claimed |
| WO-1998051772-A1 | ENZYMATIC BLEACHING SYSTEM CONTAINING NEW COMPOUNDS FOR INTENSIFYING ENZYMATIC ACTION | CALL, KRIMHILD (DE) | 1998-11-19 | — | — | WO | claimed |
| EP-0327263-B1 | Hair growth stimulation with nitroxide and other radicals | PROCTOR PETER H (US) | 1994-09-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041716-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING HYPERCHOLESTEROLEMIA | TXNRD2, TET1, TXNRD3 | GSK3A 3740/4885GSK3B 4061/4885MGLL 754/4885 |
| US-20250041285-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HMOX2, QSOX1, GPX1 | GSK3A 4746/4885GSK3B 4829/4885MGLL 3233/4885 |
| US-20100240700-A1 | PROPHYLACTIC PRETREATMENT WITH ANTIOXIDANTS | GPX1, GPX4, SOD1 | GSK3A 1825/4885GSK3B 1929/4885MGLL 2751/4885 |
| US-20240415826-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | TXNRD2, TXN2, TXNRD1 | GSK3A 4797/4885GSK3B 4857/4885MGLL 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.